Abstract
The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In case of serious or even life-threatening bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, anticoagulant treatment can be reversed by various specific strategies. Heparin and heparin derivatives can be counteracted by protamine sulphate, whereas the anticoagulant effect of vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates. The anti-hemostatic effect of aspirin and other anti-platelet strategies can be corrected by the administration of platelet concentrate or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors has been introduced and most of these agents are presently being evaluated in clinical studies. The new generation anticoagulants include specific inhibitors of factor IIa, factor Xa (including pentasaccharides) and agents that interfere with tissue factor activity. A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although in some cases the administration of recombinant factor VIIa may be an option.
Similar content being viewed by others
References
Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ (2008) Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:110S–112S
Mannucci PM, Levi M (2007) Prevention and treatment of major blood loss. N Engl J Med 356:2301–2311
Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:257S–298S
Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782
Algra A (2007) Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 6:115–124
Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI (2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:141S–159S
Lindblad B, Borgstrom A, Wakefield TW, Whitehouse WM Jr, Stanley JC (1987) Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res 48:31–40
Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M (1986) Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 16:139–146
Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR (1990) Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 63:271–274
Bang CJ, Berstad A, Talstad I (1991) Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis 21:155–160
Caplan SN, Berkman EM (1976) Letter: protamine sulfate and fish allergy. N Engl J Med 295:172
Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN (1997) Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 13:394–397
Mauney MC, Buchanan SA, Lawrence WA, Bishop A, Sinclair K, Daniel TM, Tribble CG, Kron IL (1995) Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg 22:264–269
Dellagrammaticas D, Lewis SC, Gough MJ (2008) Is heparin reversal with protamine after carotid endarterectomy dangerous? Eur J Vasc Endovasc Surg 36:41–44
D’Ambra M (1996) Restoration of the normal coagulation process: advances in therapies to antagonize heparin. J Cardiovasc Pharmacol 27 (suppl 1):S58–S62
Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Zimmermann JJ, Lappas DG (1994) In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg 79:670–674
Tao W, Deyo DJ, Brunston RL Jr, Vertrees RA, Zwischenberger JB (1998) Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device—an alternative to protamine. Crit Care Med 26:1096–1102
Buller HR (2002) Treatment of symptomatic venous thromboembolism: improving outcomes. Semin Thromb Hemost 28(suppl 2):41–48
Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879
Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106:2550–2554
Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M (2004) Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 124:653–658
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:160S–198S
Dentali F, Ageno W, Crowther M (2006) Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 4:1853–1863
Baglin T (1998) Management of warfarin (coumarin) overdose. Blood Rev 12:91–98
Whitling AM, Bussey HI, Lyons RM (1998) Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 158:2136–2140
Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE (2001) A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 115:145–149
Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W (2002) Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 137:251–254
Weibert RT, Le DT, Kayser SR, Rapaport SI (1997) Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 126:959–962
Nee R, Doppenschmidt D, Donovan DJ, Andrews TC (1999) Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 83:286–287
Raj G, Kumar R, McKinney WP (1999) Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 159:2721–2724
Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D (2003) Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 163:2469–2473
Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O’malley PG (2006) Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 166:391–397
van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, de Vries-Goldschmeding HJ, Rakers E, Levi M (2007) Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon. Thromb Haemost 98:747–755
Martin JC (1991) Anaphylactoid reactions and vitamin K. Med J Aust 155:851
Fiore LD, Scola MA, Cantillon CE, Brophy MT (2001) Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 11:175–183
Dentali F, Ageno W (2004) Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica 89:857–862
Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M (2007) Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82:82–92
Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF (1997) Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77:477–480
Yasaka M, Sakata T, Naritomi H, Minematsu K (2005) Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 115:455–459
Junagade P, Grace R, Gover P (2007) Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology 12:439–440
van AL, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF (2006) Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118:313–320
Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM (2006) Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 4:967–970
Kessler CM (2006) Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost 4:963–966
Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H (2008) Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 6:622–631
Leissinger CA, Blatt PM, Hoots WK, Ewenstein B (2008) Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 83:137–143
Levi M (2007) Disseminated intravascular coagulation. Crit Care Med 35:2191–2195
Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U (1998) The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 9:741–748
Dager WE, King JH, Regalia RC, Williamson D, Gosselin RC, White RH, Tharratt RS, Albertson TE (2006) Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 26:1091–1098
Deveras RA, Kessler CM (2002) Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 137:884–888
Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J (2003) Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 14:469–477
Levi M (2005) New antithrombotics in the treatment of thromboembolic disease. Eur J Intern Med 16:230–237
Strebel N, Prins M, Agnelli G, Buller HR (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162:1451–1456
Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, van Boeckel CA, Meuleman DG (2002) Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents—the selective factor Xa inhibitors. Cardiovasc Drug Rev 20:37–52
Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G (2001) Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 161:2215–2221
Weitz JI, Buller HR (2002) Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105:1004–1011
Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H (2002) Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 107:93–99
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956
Woltz M, Levi M, Sarich TC, Bostrom SL, Ericksson UG, Erikkson M, Svensson M, Weitz JI, Elg M, Wahlander K (2004) Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers Thromb Haemost 91(6):1090–1096
Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S (2007) Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116:180–187
Shantsila E, Lip GY (2008) Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 9:1020–1033
Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP (1996) Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci USA 93:2149–2154
Moons AH, Peters RJ, Bijsterveld NR, Piek JJ, Prins MH, Vlasuk GP, Rote WE, Buller HR (2003) Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 41:2147–2153
Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van der MJ, Piovella F, Raskob G, Gent M (2001) Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104:74–78
Allen GA, Hoffman M, Roberts HR, Monroe DM III (2002) Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth 49:S7–S14
Hedner U, Erhardtsen E (2002) Potential role for rFVIIa in transfusion medicine. Transfusion 42:114–124
Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR (2001) Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 103:2555–2559
Patrono C, Baigent C, Hirsh J, Roth G (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133:199S–233S
Merritt JC, Bhatt DL (2004) The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 17:21–27
Ferrari E, Benhamou M, Cerboni P, Marcel B (2005) Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45:456–459
Richardson DW, Robinson AG (1985) Desmopressin. Ann Intern Med 103:228–239
Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B (2003) Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 102:4594–4599
Anonymous (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee (see comments). Lancet 348:1329–1339
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502
Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc Interv 69:334–340
Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ (2007) Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 5:82–90
Leithauser B, Zielske D, Seyfert UT, Jung F (2008) Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc 39:293–302
Reiter R, Jilma-Stohlawetz P, Horvath M, Jilma B (2005) Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide. Transfusion 45:420–426
Conflict of interest statement
The author declares that he has no conflict of interest related to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levi, M. Emergency reversal of antithrombotic treatment. Intern Emerg Med 4, 137–145 (2009). https://doi.org/10.1007/s11739-008-0201-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-008-0201-8